Annual EBIT
-$106.69 M
+$72.86 M+40.58%
31 December 2023
Summary:
Heron Therapeutics annual earnings before interest & taxes is currently -$106.69 million, with the most recent change of +$72.86 million (+40.58%) on 31 December 2023. During the last 3 years, it has risen by +$118.69 million (+52.66%). HRTX annual EBIT is now -9599.18% below its all-time high of -$800.00 thousand.HRTX EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly EBIT
-$4.46 M
+$1.99 M+30.83%
30 September 2024
Summary:
Heron Therapeutics quarterly earnings before interest & taxes is currently -$4.46 million, with the most recent change of +$1.99 million (+30.83%) on 30 September 2024. Over the past year, it has increased by +$20.47 million (+82.12%). HRTX quarterly EBIT is now -542.70% below its all-time high of $1.01 million, reached on 31 December 2010.HRTX Quarterly EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM EBIT
-$22.00 M
+$20.47 M+48.20%
30 September 2024
Summary:
Heron Therapeutics TTM earnings before interest & taxes is currently -$22.00 million, with the most recent change of +$20.47 million (+48.20%) on 30 September 2024. Over the past year, it has increased by +$103.64 million (+82.49%). HRTX TTM EBIT is now -2299.70% below its all-time high of $1.00 million, reached on 30 September 1987.HRTX TTM EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
HRTX EBIT Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +40.6% | +82.1% | +82.5% |
| 3 y3 years | +52.7% | +91.4% | +90.1% |
| 5 y5 years | +39.4% | +87.2% | +88.7% |
HRTX EBIT High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | at high | +52.7% | at high | +92.9% | at high | +90.4% |
| 5 y | 5 years | at high | +52.7% | at high | +92.9% | at high | +90.4% |
| alltime | all time | -9599.2% | +52.7% | -542.7% | +93.1% | -2299.7% | +90.4% |
Heron Therapeutics EBIT History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$4.46 M(-30.8%) | -$22.00 M(-48.2%) |
| June 2024 | - | -$6.45 M(+34.3%) | -$42.47 M(-45.8%) |
| Mar 2024 | - | -$4.80 M(-23.8%) | -$78.43 M(-26.5%) |
| Dec 2023 | -$106.69 M(-40.6%) | -$6.30 M(-74.7%) | -$106.69 M(-15.1%) |
| Sept 2023 | - | -$24.93 M(-41.2%) | -$125.64 M(-11.9%) |
| June 2023 | - | -$42.40 M(+28.2%) | -$142.59 M(-4.7%) |
| Mar 2023 | - | -$33.06 M(+31.0%) | -$149.69 M(-16.6%) |
| Dec 2022 | -$179.55 M(-17.7%) | -$25.25 M(-39.7%) | -$179.55 M(-13.8%) |
| Sept 2022 | - | -$41.88 M(-15.4%) | -$208.28 M(-4.5%) |
| June 2022 | - | -$49.50 M(-21.3%) | -$218.11 M(-4.8%) |
| Mar 2022 | - | -$62.92 M(+16.6%) | -$229.08 M(+5.0%) |
| Dec 2021 | -$218.27 M(-3.2%) | -$53.98 M(+4.4%) | -$218.27 M(-2.0%) |
| Sept 2021 | - | -$51.71 M(-14.5%) | -$222.80 M(-2.9%) |
| June 2021 | - | -$60.47 M(+16.0%) | -$229.48 M(+2.1%) |
| Mar 2021 | - | -$52.11 M(-10.9%) | -$224.76 M(-0.3%) |
| Dec 2020 | -$225.38 M(+10.9%) | -$58.51 M(+0.2%) | -$225.38 M(+3.0%) |
| Sept 2020 | - | -$58.38 M(+4.7%) | -$218.81 M(+12.0%) |
| June 2020 | - | -$55.75 M(+5.7%) | -$195.28 M(+2.1%) |
| Mar 2020 | - | -$52.73 M(+1.5%) | -$191.31 M(-5.9%) |
| Dec 2019 | -$203.28 M(+15.4%) | -$51.95 M(+49.0%) | -$203.28 M(+4.3%) |
| Sept 2019 | - | -$34.85 M(-32.7%) | -$194.88 M(-3.4%) |
| June 2019 | - | -$51.78 M(-20.0%) | -$201.80 M(+6.8%) |
| Mar 2019 | - | -$64.70 M(+48.6%) | -$188.88 M(+7.2%) |
| Dec 2018 | -$176.17 M(-9.0%) | -$43.55 M(+4.2%) | -$176.17 M(-9.0%) |
| Sept 2018 | - | -$41.78 M(+7.5%) | -$193.50 M(+0.2%) |
| June 2018 | - | -$38.85 M(-25.3%) | -$193.04 M(-1.6%) |
| Mar 2018 | - | -$51.99 M(-14.6%) | -$196.24 M(+1.4%) |
| Dec 2017 | -$193.55 M(+13.5%) | -$60.88 M(+47.4%) | -$193.55 M(+8.1%) |
| Sept 2017 | - | -$41.31 M(-1.8%) | -$179.03 M(-3.5%) |
| June 2017 | - | -$42.05 M(-14.7%) | -$185.46 M(-0.5%) |
| Mar 2017 | - | -$49.30 M(+6.3%) | -$186.47 M(+9.4%) |
| Dec 2016 | -$170.48 M(+76.4%) | -$46.37 M(-2.9%) | -$170.48 M(+10.1%) |
| Sept 2016 | - | -$47.73 M(+10.8%) | -$154.88 M(+19.5%) |
| June 2016 | - | -$43.07 M(+29.3%) | -$129.64 M(+18.3%) |
| Mar 2016 | - | -$33.31 M(+8.3%) | -$109.58 M(+13.4%) |
| Dec 2015 | -$96.63 M(+28.0%) | -$30.77 M(+36.8%) | -$96.63 M(+12.0%) |
| Sept 2015 | - | -$22.49 M(-2.3%) | -$86.28 M(+4.3%) |
| June 2015 | - | -$23.01 M(+13.0%) | -$82.74 M(+5.4%) |
| Mar 2015 | - | -$20.36 M(-0.3%) | -$78.52 M(+4.0%) |
| Dec 2014 | -$75.48 M(+38.6%) | -$20.41 M(+7.7%) | -$75.48 M(+9.6%) |
| Sept 2014 | - | -$18.95 M(+0.9%) | -$68.89 M(+10.0%) |
| June 2014 | - | -$18.79 M(+8.5%) | -$62.61 M(+6.1%) |
| Mar 2014 | - | -$17.32 M(+25.3%) | -$59.02 M(+8.4%) |
| Dec 2013 | -$54.45 M(+128.6%) | -$13.83 M(+9.2%) | -$54.45 M(+10.6%) |
| Sept 2013 | - | -$12.66 M(-16.7%) | -$49.25 M(+15.5%) |
| June 2013 | - | -$15.21 M(+19.3%) | -$42.64 M(+34.0%) |
| Mar 2013 | - | -$12.75 M(+47.9%) | -$31.81 M(+33.5%) |
| Dec 2012 | -$23.82 M(+115.4%) | -$8.62 M(+42.4%) | -$23.82 M(+23.3%) |
| Sept 2012 | - | -$6.05 M(+38.2%) | -$19.32 M(+11.3%) |
| June 2012 | - | -$4.38 M(-8.2%) | -$17.36 M(+19.6%) |
| Mar 2012 | - | -$4.77 M(+15.8%) | -$14.52 M(+31.2%) |
| Dec 2011 | -$11.06 M(+53.8%) | -$4.12 M(+0.7%) | -$11.06 M(+86.3%) |
| Sept 2011 | - | -$4.09 M(+165.5%) | -$5.94 M(+70.5%) |
| June 2011 | - | -$1.54 M(+17.1%) | -$3.48 M(-38.2%) |
| Mar 2011 | - | -$1.31 M(-230.6%) | -$5.64 M(-21.6%) |
| Dec 2010 | -$7.19 M(-29.8%) | $1.01 M(-161.6%) | -$7.19 M(-30.2%) |
| Sept 2010 | - | -$1.64 M(-55.8%) | -$10.30 M(+4.3%) |
| June 2010 | - | -$3.69 M(+28.7%) | -$9.88 M(-2.6%) |
| Mar 2010 | - | -$2.87 M(+36.7%) | -$10.14 M(-1.0%) |
| Dec 2009 | -$10.24 M(-56.3%) | -$2.10 M(+73.1%) | -$10.24 M(-14.5%) |
| Sept 2009 | - | -$1.21 M(-69.4%) | -$11.97 M(-29.7%) |
| June 2009 | - | -$3.96 M(+33.4%) | -$17.04 M(-11.8%) |
| Mar 2009 | - | -$2.97 M(-22.5%) | -$19.33 M(-17.6%) |
| Dec 2008 | -$23.45 M(-0.8%) | -$3.83 M(-39.0%) | -$23.44 M(-14.5%) |
| Sept 2008 | - | -$6.28 M(+0.4%) | -$27.43 M(+3.9%) |
| June 2008 | - | -$6.25 M(-11.8%) | -$26.39 M(+7.2%) |
| Mar 2008 | - | -$7.09 M(-9.3%) | -$24.61 M(+4.0%) |
| Dec 2007 | -$23.63 M(+25.3%) | -$7.82 M(+49.3%) | -$23.68 M(+9.7%) |
| Sept 2007 | - | -$5.24 M(+17.0%) | -$21.59 M(+6.3%) |
| June 2007 | - | -$4.47 M(-27.2%) | -$20.30 M(-1.5%) |
| Mar 2007 | - | -$6.15 M(+7.4%) | -$20.61 M(+9.3%) |
| Dec 2006 | -$18.86 M(+122.6%) | -$5.73 M(+45.0%) | -$18.86 M(+19.3%) |
| Sept 2006 | - | -$3.95 M(-17.6%) | -$15.81 M(+15.4%) |
| June 2006 | - | -$4.79 M(+8.8%) | -$13.70 M(+18.5%) |
| Mar 2006 | - | -$4.40 M(+64.5%) | -$11.56 M(+36.5%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2005 | -$8.47 M(-9.0%) | -$2.67 M(+45.6%) | -$8.47 M(+4.1%) |
| Sept 2005 | - | -$1.84 M(-30.7%) | -$8.14 M(-1.5%) |
| June 2005 | - | -$2.65 M(+102.2%) | -$8.26 M(+2.6%) |
| Mar 2005 | - | -$1.31 M(-43.9%) | -$8.05 M(-13.6%) |
| Dec 2004 | -$9.32 M(+40.9%) | -$2.34 M(+19.4%) | -$9.32 M(+9.7%) |
| Sept 2004 | - | -$1.96 M(-19.8%) | -$8.50 M(+9.3%) |
| June 2004 | - | -$2.44 M(-5.4%) | -$7.77 M(+6.2%) |
| Mar 2004 | - | -$2.58 M(+69.9%) | -$7.32 M(+10.7%) |
| Dec 2003 | -$6.61 M(+30.9%) | -$1.52 M(+22.9%) | -$6.61 M(+13.5%) |
| Sept 2003 | - | -$1.24 M(-37.8%) | -$5.82 M(-3.5%) |
| June 2003 | - | -$1.98 M(+5.9%) | -$6.03 M(+5.5%) |
| Mar 2003 | - | -$1.87 M(+156.4%) | -$5.72 M(+11.1%) |
| Dec 2002 | -$5.05 M(-31.1%) | -$731.00 K(-49.4%) | -$5.15 M(-26.2%) |
| Sept 2002 | - | -$1.44 M(-13.4%) | -$6.98 M(-6.5%) |
| June 2002 | - | -$1.67 M(+27.8%) | -$7.47 M(+2.0%) |
| Mar 2002 | - | -$1.30 M(-49.1%) | -$7.32 M(-0.1%) |
| Dec 2001 | -$7.33 M(+70.2%) | -$2.56 M(+32.6%) | -$7.33 M(+12.4%) |
| Sept 2001 | - | -$1.93 M(+27.0%) | -$6.52 M(+19.0%) |
| June 2001 | - | -$1.52 M(+15.8%) | -$5.48 M(+10.2%) |
| Mar 2001 | - | -$1.31 M(-25.1%) | -$4.97 M(+13.7%) |
| Dec 2000 | -$4.31 M(+153.4%) | -$1.75 M(+96.6%) | -$4.38 M(+33.2%) |
| Sept 2000 | - | -$892.00 K(-12.0%) | -$3.29 M(+6.9%) |
| June 2000 | - | -$1.01 M(+41.6%) | -$3.07 M(+85.2%) |
| Mar 2000 | - | -$716.10 K(+7.8%) | -$1.66 M(+382.6%) |
| Dec 1999 | -$1.70 M(-19.0%) | -$664.50 K(-2.2%) | -$344.00 K(-85.5%) |
| Sept 1999 | - | -$679.50 K(-269.9%) | -$2.38 M(+83.0%) |
| June 1999 | - | $400.00 K(-33.3%) | -$1.30 M(-7.1%) |
| Mar 1999 | - | $600.00 K(-122.2%) | -$1.40 M(-17.6%) |
| Dec 1998 | -$2.10 M(+90.9%) | -$2.70 M(-775.0%) | -$1.70 M(+750.0%) |
| Sept 1998 | - | $400.00 K(+33.3%) | -$200.00 K(-77.8%) |
| June 1998 | - | $300.00 K(0.0%) | -$900.00 K(-43.8%) |
| Mar 1998 | - | $300.00 K(-125.0%) | -$1.60 M(+23.1%) |
| Dec 1997 | -$1.10 M(-87.1%) | -$1.20 M(+300.0%) | -$1.30 M(-58.1%) |
| Sept 1997 | - | -$300.00 K(-25.0%) | -$3.10 M(-35.4%) |
| June 1997 | - | -$400.00 K(-166.7%) | -$4.80 M(-22.6%) |
| Mar 1997 | - | $600.00 K(-120.0%) | -$6.20 M(-27.1%) |
| Dec 1996 | -$8.50 M(-1.2%) | -$3.00 M(+50.0%) | -$8.50 M(-4.5%) |
| Sept 1996 | - | -$2.00 M(+11.1%) | -$8.90 M(-1.1%) |
| June 1996 | - | -$1.80 M(+5.9%) | -$9.00 M(-2.2%) |
| Mar 1996 | - | -$1.70 M(-50.0%) | -$9.20 M(+9.5%) |
| Dec 1995 | -$8.60 M(-4.4%) | -$3.40 M(+61.9%) | -$8.40 M(+23.5%) |
| Sept 1995 | - | -$2.10 M(+5.0%) | -$6.80 M(-9.3%) |
| June 1995 | - | -$2.00 M(+122.2%) | -$7.50 M(-9.6%) |
| Mar 1995 | - | -$900.00 K(-50.0%) | -$8.30 M(-10.8%) |
| Dec 1994 | -$9.00 M(-13.5%) | -$1.80 M(-35.7%) | -$9.30 M(-10.6%) |
| Sept 1994 | - | -$2.80 M(0.0%) | -$10.40 M(+1.0%) |
| June 1994 | - | -$2.80 M(+47.4%) | -$10.30 M(-1.0%) |
| Mar 1994 | - | -$1.90 M(-34.5%) | -$10.40 M(-1.9%) |
| Dec 1993 | -$10.40 M(+62.5%) | -$2.90 M(+7.4%) | -$10.60 M(+7.1%) |
| Sept 1993 | - | -$2.70 M(-6.9%) | -$9.90 M(+20.7%) |
| June 1993 | - | -$2.90 M(+38.1%) | -$8.20 M(+28.1%) |
| Mar 1993 | - | -$2.10 M(-4.5%) | -$6.40 M(0.0%) |
| Dec 1992 | -$6.40 M(+60.0%) | -$2.20 M(+120.0%) | -$6.40 M(+16.4%) |
| Sept 1992 | - | -$1.00 M(-9.1%) | -$5.50 M(-3.5%) |
| June 1992 | - | -$1.10 M(-47.6%) | -$5.70 M(+14.0%) |
| Mar 1992 | - | -$2.10 M(+61.5%) | -$5.00 M(+22.0%) |
| Dec 1991 | -$4.00 M(-14.9%) | -$1.30 M(+8.3%) | -$4.10 M(+2.5%) |
| Sept 1991 | - | -$1.20 M(+200.0%) | -$4.00 M(-2.4%) |
| June 1991 | - | -$400.00 K(-66.7%) | -$4.10 M(-14.6%) |
| Mar 1991 | - | -$1.20 M(0.0%) | -$4.80 M(+4.3%) |
| Dec 1990 | -$4.70 M(-11.3%) | -$1.20 M(-7.7%) | -$4.60 M(-2.1%) |
| Sept 1990 | - | -$1.30 M(+18.2%) | -$4.70 M(+4.4%) |
| June 1990 | - | -$1.10 M(+10.0%) | -$4.50 M(0.0%) |
| Mar 1990 | - | -$1.00 M(-23.1%) | -$4.50 M(+50.0%) |
| Dec 1989 | -$5.30 M(-10.2%) | -$1.30 M(+18.2%) | -$3.00 M(-68.8%) |
| Sept 1989 | - | -$1.10 M(0.0%) | -$9.60 M(+21.5%) |
| June 1989 | - | -$1.10 M(-320.0%) | -$7.90 M(+25.4%) |
| Mar 1989 | - | $500.00 K(-106.3%) | -$6.30 M(+6.8%) |
| Dec 1988 | -$5.90 M(+43.9%) | -$7.90 M(-1416.7%) | -$5.90 M(+90.3%) |
| Sept 1988 | - | $600.00 K(+20.0%) | -$3.10 M(-8.8%) |
| June 1988 | - | $500.00 K(-44.4%) | -$3.40 M(-2.9%) |
| Mar 1988 | - | $900.00 K(-117.6%) | -$3.50 M(-14.6%) |
| Dec 1987 | -$4.10 M | -$5.10 M(-1800.0%) | -$4.10 M(-510.0%) |
| Sept 1987 | - | $300.00 K(-25.0%) | $1.00 M(+42.9%) |
| June 1987 | - | $400.00 K(+33.3%) | $700.00 K(+133.3%) |
| Mar 1987 | - | $300.00 K | $300.00 K |
FAQ
- What is Heron Therapeutics annual earnings before interest & taxes?
- What is the all time high annual EBIT for Heron Therapeutics?
- What is Heron Therapeutics annual EBIT year-on-year change?
- What is Heron Therapeutics quarterly earnings before interest & taxes?
- What is the all time high quarterly EBIT for Heron Therapeutics?
- What is Heron Therapeutics quarterly EBIT year-on-year change?
- What is Heron Therapeutics TTM earnings before interest & taxes?
- What is the all time high TTM EBIT for Heron Therapeutics?
- What is Heron Therapeutics TTM EBIT year-on-year change?
What is Heron Therapeutics annual earnings before interest & taxes?
The current annual EBIT of HRTX is -$106.69 M
What is the all time high annual EBIT for Heron Therapeutics?
Heron Therapeutics all-time high annual earnings before interest & taxes is -$800.00 K
What is Heron Therapeutics annual EBIT year-on-year change?
Over the past year, HRTX annual earnings before interest & taxes has changed by +$72.86 M (+40.58%)
What is Heron Therapeutics quarterly earnings before interest & taxes?
The current quarterly EBIT of HRTX is -$4.46 M
What is the all time high quarterly EBIT for Heron Therapeutics?
Heron Therapeutics all-time high quarterly earnings before interest & taxes is $1.01 M
What is Heron Therapeutics quarterly EBIT year-on-year change?
Over the past year, HRTX quarterly earnings before interest & taxes has changed by +$20.47 M (+82.12%)
What is Heron Therapeutics TTM earnings before interest & taxes?
The current TTM EBIT of HRTX is -$22.00 M
What is the all time high TTM EBIT for Heron Therapeutics?
Heron Therapeutics all-time high TTM earnings before interest & taxes is $1.00 M
What is Heron Therapeutics TTM EBIT year-on-year change?
Over the past year, HRTX TTM earnings before interest & taxes has changed by +$103.64 M (+82.49%)